Tech Company Financing Transactions

Ultragenyx Pharmaceutical Funding Round

On 6/20/2011, Ultragenyx Pharmaceutical raised $45 million in Series A funding from F-Prime Capital, TPG Biotech and Healthcap Venture Capital.

Transaction Overview

Announced On
6/20/2011
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors

F-Prime Capital (Lead Investor) (Benjamin Auspitz)

TPG Biotech (Lead Investor) (Eran Nadav)

Healthcap Venture Capital

Pappas Ventures

Proceeds Purpose
This funding will advance multiple rare disease product programs in the pipeline, as well as the development of new product candidates and partnerships.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
60 Leveroni Ct.
Novato, CA 94949
USA
Email Address
Overview
Ultragenyx (NASDAQ: RARE) is focused on developing therapeutics for rare diseases. The company will build on management's experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
Profile
Ultragenyx Pharmaceutical LinkedIn Company Profile
Social Media
Ultragenyx Pharmaceutical Company Twitter Account
Company News
Ultragenyx Pharmaceutical News
Facebook
Ultragenyx Pharmaceutical on Facebook
YouTube
Ultragenyx Pharmaceutical on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Emil Kakkis
  Emil Kakkis LinkedIn Profile  Emil Kakkis Twitter Account  Emil Kakkis News  Emil Kakkis on Facebook
Chief Financial Officer
Shalini Sharp
  Shalini Sharp LinkedIn Profile  Shalini Sharp Twitter Account  Shalini Sharp News  Shalini Sharp on Facebook
Chief Operating Officer
John Pinion
  John Pinion LinkedIn Profile  John Pinion Twitter Account  John Pinion News  John Pinion on Facebook
VP - Bus. Development
Thomas Kassberg
  Thomas Kassberg LinkedIn Profile  Thomas Kassberg Twitter Account  Thomas Kassberg News  Thomas Kassberg on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/20/2011: iControl Networks venture capital transaction
Next: 6/20/2011: Apellis Pharmaceuticals venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary